Peptides for Men Over 60

Aggressive GH-axis stacking, anything that raises IGF-1 supraphysiologically, and compounds without published long-term safety data move out of the recommended set at this age.

• 01

  MK-677 — IGF-1 elevation without a clear cancer-screening protocol

• 02

  IGF-1 LR3 — growth signaling that amplifies any undiagnosed neoplasm

• 03

  Melanotan II — pigmentation changes mask melanoma screening

• 04

  High-dose CJC-1295 DAC stacks — unnecessary GH push at this age

Past 60, peptide use is judged by what it preserves rather than what it adds. The compounds that earn a place are the ones with the longest human safety record and the clearest mechanism for maintaining immune function, joint integrity, and recovery from minor injury and illness. Every other reason is weaker than it sounds.

• 01

  Documented thymic involution markers (low naive T-cell counts, recurrent infections) — thymic-support compounds have the cleanest case here.

• 02

  Joint or tendon issues limiting daily mobility or training — BPC-157 has the strongest safety-and-evidence profile.

• 03

  Slow recovery from minor surgery, illness, or training stress — short BPC-157 or GHK-Cu courses are reasonable.

• 04

  Mild cognitive complaints with normal screening labs — discuss with your physician before any compound; do not self-treat memory or focus concerns.

Conservative dosing, full screening, and ongoing clinical coordination are not optional past 60. The compounds with the longest track records have the cleanest fit; the novel ones with thin human data do not. Every cycle should have a written stop criterion and a screening cadence built in.

• 01

  Full physical, age-appropriate cancer screening, lipid panel, fasting glucose, and PSA current within 12 months — refresh before every new cycle.

• 02

  Single compound at a time; avoid stacking unless coordinated with a clinician familiar with both compounds.

• 03

  Disclose every research peptide to your primary care physician and any prescribing specialist — interactions with anticoagulants, BP medications, and diabetes care matter.

• 04

  Track function, not just labs: gait speed, hand-grip strength, sleep duration, recovery from a typical day's exertion. Functional decline trumps lab improvement.

Past 60, the relationship with primary care becomes the foundation of any safe peptide protocol. The same compound is safe in the context of full clinical coordination and risky without it. Use each visit to confirm the protocol still fits the current medication list, screening status, and recent labs.

• 01

  Every active and recently-stopped peptide, with start dates, doses, and duration.

• 02

  Any new symptoms — fatigue, joint pain, urinary changes, skin changes, mood shifts — to rule out interaction or unmasked pathology.

• 03

  Updated medication and supplement list, including OTC anti-inflammatories.

• 04

  Any change in cancer screening status, cardiovascular workup, or sleep complaints.